Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Adjuvant Radiotherapy plus Sintilimab vs TACE for Postoperative Narrow-Margin Hepatocellular Carcinoma
ChiCTR2500115642Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 2-year recurrence-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500115642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115642.